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The microbiota of the gastrointestinal tract is frequently mentioned as one of the key players in the etiopathogenesis of Crohn’s
disease(CD).Fourhypotheses havebeensuggested:thesingle,stillunknownbacterialpathogen,anabnormaloverallcomposition
of the bowel microbiota (“dysbiosis”), an abnormal immunological reaction to an essentially normally composed microbiota,
and increased bacterial translocation. We propose that laser capture microdissection of selected microscopic structures, followed
by broad-range 16S rRNA gene sequencing, is an excellent method to assess spatiotemporal alterations in the composition of
the bowel microbiota in CD. Using this approach, we demonstrated signiﬁcant changes of the composition, abundance, and
location of the gut microbiome in this disease. Some of these abnormal ﬁndings persisted even after macroscopic mucosal healing.
Further investigations along these lines may lead to a better understanding of the possible involvement of the bowel bacteria in the
development of clinical Crohn’s disease.
1.Introduction
Crohn’s disease (CD) is characterized by chronic, segmental,
transmural inﬂammation of the entire gastrointestinal tract.
Although the exact etiology of the disease is still unclear,
it is generally assumed to originate from immunologic
changesinducedbyenvironmentalinﬂuencesinagenetically
suspectible host. The ﬁrst discovered CD susceptibility
gene was the Caspase Recruitment Domain 15 (CARD15)
on chromosome 16q [1, 2]. The protein product of this
gene is present in monocytes, dentritic cells, Paneth cells,
and intestinal epithelial cells. It recognizes a breakdown
product of the bacterial cell wall, muramyl dipeptide, via
its carboxyterminal leucine rich repeat region (LRR). Sub-
sequently, it activates NFκB. Three single nucleotide poly-
morphisms (SNPs) of the CARD15 gene (Arg702Trp-SNP8,
Gly908Arg-SNP12 and Leu1007fsinsC-SNP13) are associ-
ated with CD in the Caucasian population [3–7]. These 3
SNPs may interfere with the function of the LRR, potentially
leading to a disturbance of the normal relationship between
the human host and their bowel microbiota. Bacteria have
indeed been suggested as one of the most important envi-
ronmental factors in the pathogenesis of CD. Currently, four
hypotheses are proposed. First, the disease may be caused by
asingle,stillunidentiﬁed bacterialpathogen(Mycobacterium
avium subsp. paratuberculosis (MAP) and adherent-invasive
Escherichia coli are possible candidates) [8–11]. Second, the
normal balance between beneﬁcial and harmful bacterial
species in the mucosa-associated microbiota may be dis-
turbed, so-called “dysbiosis” [12–14]. Third, the mucosa
may be abnormally permeable to bacteria or their products
(increased bacterial translocation) [12]. Finally, the immune
system may react excessively to a normally composed bowel
microbiota [15]. If any of these four assumptions are true,2 International Journal of Inﬂammation
Table 1: Patient characteristics.
Patient Sex Age Diagnosis CARD15-SNP8 CARD15-SNP12 CARD15-SNP13 Procedure
1( ∗) ♂ 32 CD WT WT WT Right hemicolectomy
2( ∗) ♀ 36 CD HE WT WT Right hemicolectomy
3( ∗) ♂ 22 CD HE HE WT Right hemicolectomy
4( ∗) ♂ 18 CD HO WT WT Right hemicolectomy
5 ♂ 38 ASLC ND ND ND Colonoscopy
6( ∗∗) ♂ 70 ASLC ND ND ND Colonoscopy
7 ♀ 17 PMC ND ND ND Colonoscopy
8( §) ♂ 64 PMC ND ND ND Colonoscopy
9 ♀ 75 DIV ND ND ND Colonoscopy
10 (§§) ♂ 48 DIV ND ND ND Colonoscopy
11 (∗) ♀ 65 AC WT WT WT Right hemicolectomy
12 (∗) ♀ 55 AC WT WT WT Total colectomy
13 (∗) ♀ 65 AC HE WT WT Total colectomy
ASLC: acute self-limited colitis, PMC: pseudomembranous colitis, DIV: diverticulitis, AC: adenocarcinoma.
WT: wild type, HE: heterozygous, HO: homozygous, ND: Not determined.
SNP8: Arg702Trp, SNP12: Gly908Arg, SNP13: Leu1007fsinsC.
(∗) Treated with preoperative antibiotic coverage (cefazoline 2g IV + metronidazole 1.5g IV at induction).
(∗∗) Treated with amoxicillin for 2 weeks prior to colonoscopy.
(§) Clostridium diﬃcile toxin assay positive.
(§§) Treated with amoxicillin + clavulanic acid and levoﬂaxacin for 10 days prior to colonoscopy.
bowel biopsies from carriers of the 3 CD-associated CARD15
SNPs may contain unexpected bacteria or an abnormally
composed microbiota in unusual locations.
Testing this hypothesis is complicated by the fact that 70
to 80% of the intestinal bacteria are currently unculturable
becauseoffastidiousorevenunknowngrowthrequirements.
Culture-independent, molecular detection, and identiﬁca-
tion techniques are therefore recommended [16]. One
commonlyusedapproachisbasedonthestructureofthe16S
ribosomal RNA (rRNA) gene. This 1550 base pair long gene
is found exclusively in bacteria. Its presence on the bacterial
c h r o m o s o m ei no n eo rm o r ec o p i e si sn e c e s s a r yf o rn o r m a l
growth and metabolism. The 16S rDNA contains both
highlyconservedandhypervariable(V)regions,allowingthe
construction of universal primers and facilitating bacterial
identiﬁcation up to the (sub)species level, respectively [17].
This technique has been commonly applied to faecal samples
and mucosal biopsies [18]. However, a combination with
laser-capture microdissection (LCM) would allow to allocate
individual bacterial sequences to speciﬁc tissue compart-
ments (e.g., the muscular layer of the bowel wall) or even
microscopic lesions of interest, such as ulcers, dilated lymph
vessels with surrounding inﬂammatory inﬁltrate, and gran-
ulomas. We have applied this combined approach to surgical
biopsies obtained from CD patients, and we have compared
ourresultswiththoseobtainedin(non)microdissectedtissue
samples from disease and healthy controls.
2.MaterialsandMethods
2.1. Patients. Four CD patients, 6 disease controls (acute
nonchronic gastrointestinal tract inﬂammation), and 3
healthy controls (normal mucosa at a large distance from
a nonstenosing colorectal adenocarcinoma) were included
(Table 1). Genotypes for the 3 CD-associated CARD15 SNPs
weredeterminedfortheCDpatientsandthehealthycontrols
using a salting out procedure starting from venous blood
[19]. One to six transmural biopsies were obtained from
(ileo)colectomy specimens of these patients after longitudi-
nal opening of the bowel wall and ﬂushing with tap water
to remove residual bowel contents. For the disease controls,
mucosal biopsies were obtained during colonoscopy. All
biopsies were snap-frozen and stored at −80◦C. One 5μm-
thick slide from each biopsy was haematoxylin-eosin stained
and evaluated microscopically to conﬁrm the diagnosis and,
if applicable, to select areas suitable for LCM (Tables 2 and 3,
Figure 1).
2.2. Laser-Capture Microdissection and DNA Extraction. For
L C M ,t w ot of o u r1 4μm-thick tissue sections were prepared
using presterilized microtome blades and UV-irradiated
PALMMembraneSlides(PALMMicrolaserTechnologiesAG,
Bernried, Germany). Sections were ﬁxed for 1 minute in
100% ethanol, dried for 15min at 37◦C ,a n dh y d r a t e di na
decreasing concentration range of ethanol. After hydration,
the slides were stained with Mayer’s haematoxylin for 1min,
dehydrated in an increasing concentration range of ethanol,
and air-dried under a fume hood for 5min. The PALM
Robot-MicroBeam System was used for microdissection and
dissected tissue was captured in inverted Eppendorf tube
caps ﬁlled with 50μLT Eb u ﬀer (10mM Tris-HCl pH 8.0,
1mM EDTA). Endoscopic biopsies and lymph node tissues
harvested from surgical specimens were submitted to DNA
extraction directly.
Tissue was digested overnight with 50μL 2x digestion
buﬀer (SDS 2%, 50mM EDTA, 0.12% proteinase K) at 55◦CInternational Journal of Inﬂammation 3
Table 2: Histological structures and lesions selected for LCM.
Patient Normal mucosa (∗∗) Pathological mucosa (∗)( ∗∗) Ulcer base (∗) Myenteric plexus (∗)
1 IL (sample 1) Il + COL (sample 5) Il + COL (sample 9) Il + COL (sample 12)
2 IL (sample 2) Il + COL (sample 6) NA Il + COL (sample 13)
3 IL (sample 3) Il + COL (sample 7) Il + COL (sample 10) Il + COL (sample 14)
4 IL (sample 4) Il + COL (sample 8) Il + COL (sample 11) Il + COL (sample 15)
11 IL (sample 26) NA NA IL (sample 30)
11 COL (sample 27) NA NA COL (sample 31)
12 COL (sample 28) NA NA COL (sample 32)
13 COL (sample 29) NA NA COL (sample 33)
IL: ileum; COL: colon; NA: Not applicable.
(∗) IL + COL pooled per patient.
(∗∗) The superﬁcial half of the mucosa, the surface epithelium, and the adherent mucus were microdissected.
200µm
(a)
200µm
(b)
Figure 1: Myenteric plexus before and after microdissection (Cresyl violet, ×50).
Table 3: Tissue samples which were not microdissected.
Patient Lymph node Mucosal biopsy
1 I L+C O L( s a m p l e1 6 ) N A
2 I L+C O L( s a m p l e1 7 ) N A
3 I L+C O L( s a m p l e1 8 ) N A
4 I L+C O L( s a m p l e1 9 ) N A
5 NA COL (sample 20)
6 NA COL (sample 21)
7 NA COL (sample 22)
8 NA COL (sample 23)
9 NA COL (sample 24)
10 NA COL (sample 25)
IL: ileum; COL: colon; NA: Not applicable.
followed by heat inactivation of proteinase K at 90◦C
(25min). DNA was extracted using phenol:chloroform:
isoamylacohol (25:24:1) in Heavy Phase Lock Gel tubes
(Eppendorf AG, Hamburg, Germany) and dissolved in
40μL autoclaved TE buﬀer for storage at −20◦C. D3S3332,
ah u m a ng e n o m i cD N Am a r k e rw i t hal e n g t ho f2 1 5b a s e
pairs (GenBank: Z38904; forward primer: 5 -GCATTT-
AATGCACTAGATGCTCT-3 ; reverse primer: 5 -CTTTAA-
ATGCCAATTACAGTGCA-3 ), was ampliﬁed from all speci-
Table 4: PCR primers.
Primer Primer sequence (5  → 3 )
342f CTACGGGRSGCAGCAG
515f GTGCCAGCMGCCGCGGTAATWC
1512r TACGGYTACCTTGTTACGACTT
M = A:C,W= A:T ,R= A:G,S= C:G,Y= C:T(all1:1).
mens guaranteeing DNA extraction eﬃciency and excluding
the presence of PCR inhibitors (data not shown).
2.3. PCR Ampliﬁcation of 16S rDNA. A 998 base pair DNA
fragment including the V3 to V9 regions of the 16S rRNA
gene was ampliﬁed from all samples using a two rounds,
heminested PCR and universal primers (1st round, primer
pair: 342f/1512r; 2nd round: 515f/1512r) (Table 4). For
the ﬁrst round, 4μL template DNA solution was added
to 26μL PCR mixture, obtaining ﬁnal concentrations of
1x PCR buﬀer, 5.5mM MgCl2, 0.2mM dNTPs, 0.25μM
of each primer and 0.75U AmpliTaq Gold DNA poly-
merase (Applied Biosystems, Nieuwerkerk a/d Ijssel, The
Netherlands). DNA was ﬁrst denatured at 95◦Cf o r1 0
m i n u t e s .T h e naﬁ r s tP C Rr o u n do f3 0c y c l e s( d e n a t u r a t i o n
95◦C, 30sec/annealing 55◦C, 30sec/extension 72◦C, 2min)4 International Journal of Inﬂammation
was performed on a Tetrad-2 Thermal Cycler (Bio-Rad
laboratories Inc, Calif, USA). Four μL of unpuriﬁed product
ofthisroundwasusedastemplateforthesecondPCRround,
which also consisted of 30 cycles. Positive and negative
controls(4μLofa1/100dilutedsolutionofEscherichiacoliin
LB-medium with an optical density of 0.058, and 4μLo fT E
buﬀer, resp.) were processed simultaneously in every round.
All solvents and plastic consumables were sterilized before
use.
2.4. PCR Product Analysis. T h ep r o d u c t so ft h e2 n dP C R
round were analysed by standard agarose gel electrophoresis.
Ampliﬁed DNA of the predicted size was excised and
puriﬁed using the QIAquick Gel Extraction Kit (QIAGEN
BeneluxBV,Venlo,TheNetherlands).PuriﬁedPCRproducts
were ligated into pCR 2.1-TOPO plasmid vector using
the TOPO TA Cloning Kit. Plasmids were then ampliﬁed
in TOP10 One Shot Electrocompetent Cells (Invitrogen
NV, Merelbeke, Belgium). Transformed cells were cultured,
and ampliﬁed plasmids obtained from 8 to 48 randomly
selected colonies per sample were isolated and puriﬁed
using the QIAprep Turbo BioRobot Kit on a Biorobot 8000
Workstation (QIAGEN GmbH, Hilden, Germany). 16rDNA
sequences were then determined by cycle sequencing using
BigDye Terminator (Applied Biosystems Inc, Calif, USA)
withM13F(5 -GTAAAACGACGGCCAG-3 )andM13R(5 -
CAGGAAACAGCTATGAC-3 ) as primers. The sequences
were analysed on an ABI PRISM 3730 sequencer (Applied
Biosystems) and trimmed to remove vector sequence. All
sequences longer than 100 nucleotides and having a greater
than 98% similarity were clustered into singular opera-
tional taxonomic units (OTUs) using the ClustalW program
(version 1.83, European Bioinformatics Institute), whereby
OTUs are deﬁned as groups of sequences sharing at least
98% similarity [20]. For every OTU, the sequence with the
lowest number of ambiguous nucleotides was analysed with
theBasicLocalAlignmentSearchTool(BLAST2.2.24release,
National Center for Biotechnology Information) against
the GenBank database (release 182.0). Human and vector
sequences were excluded from further analysis. Possible
chimeras were likewise excluded after detection using the
Chimera Check program (version 2.7) of the Ribosomal
Database Project-II (RDP-II, release 9.46). An OTU was
identiﬁed as a particular species when it showed at least
98% similarity with a cultured, phenotypically identiﬁed
bacterial species in the databank [21]. Sequences not achiev-
ing the 98% limit were assigned to the family level of
the taxonomical hierarchy proposed in Bergey’s Manual of
Systematic Bacteriology [22] using the classiﬁer tool of the
Ribosomal Database Project-II with a conﬁdence threshold
of 80%. To estimate the diversity within each sample, the
cumulative number of noncontaminant bacterial families
was plotted against the cumulative number of analysed
bacterial sequences.
2.5. Statistics. Samples were compared for the abundance of
various bacterial taxa using the Fisher’s Exact test. P values
<0.05 were considered statistically signiﬁcant.
3. Results
3.1. PCR Yield and Comparison of Microdissected and Non-
Microdissected Tissues. Ampliﬁed DNA with the predicted
lengthof1kbwasobtainedafter2PCRroundsinall33tissue
samples from the 13 patients. The external positive control
yielded the expected product and the negative controls
remained blank after 30 cycles each. Sequencing of plasmid
inserts after cloning resulted in 1161 sequences longer than
100 base pairs. Overall, 410 of these (35%) originated from
genuinely present bacteria belonging to 4 phyla: Proteobac-
teria (51%), Firmicutes (28%), Actinobacteria (12%), and
Bacteroidetes (9%). These 410 sequences could be further
c l a s s i ﬁ e di n t o2 0d i ﬀerent families, and 147 sequences
(36%) were identiﬁed unambiguously at the species level:
Escherichia coli (17.5%), Kocuria rosea (6.6%), Propionibac-
terium acnes (2.9%), Enterococcus faecalis (2.2%), Lactobacil-
lus rhamnosus (1.7%), Streptococcus mitis (1.7%), Eubac-
terium rectale (1.5%), Bacteroides fragilis (0.7%), Clostridium
nexile (0.2%), Bacteroides eggerthii (0.2%), and Bacteroides
uniformis (0.2%) (Table 5). No Faecalibacterium prausnitzii
was identiﬁed on species level in the CD cases. Of the 751
remaining sequences, 55 were due to primer misalignment,
3 were likely chimeric, 187 originated from human DNA,
and506werederivedfromprobablecontaminantsbelonging
to the classes of the Alpha- and Betaproteobacteria and the
families Pseudomonadaceae and Staphylococcaceae. Ampli-
ﬁed contaminating DNA was signiﬁcantly more commonly
encountered in PCR products from microdissected versus
non-microdissected tissues (71.0% and 1.4% of all bacterial
sequences, resp.). The same applied to the proportion of
sample-derived sequences of human instead of bacterial
origin (47.0% and 2.4% in microdissected versus non-
microdissected tissues, resp.) (Fisher’s Exact test: P<0.001
in both occasions). The cumulative numbers of detected
genuinely present bacterial families plotted against the total
numbers of analysed bacterial sequences revealed increas-
ing slopes for most microdissected samples, while reach-
ing asymptotic values for the non-microdissected tissues
(Figure 2).
3.2. Comparison of the Microbiota in Crohn’s Disease and
Controls. Microdissectednormalilealmucosafromahealthy
control yielded only 1 sequence, which was derived from
the family of the Enterobacteriaceae. Normal colon mucosa
yielded more sequences, pointing to a more abundant
adherent microbiota which also contained strictly anaerobic
bacteria (Bacteroidetes). Microbiota diversity was higher in
the disease controls, with variation even between cases with
an identical diagnosis. For example, one case of acute self-
limited colitis showed a preponderance of sequences derived
from Enterobacteriaceae while no potential pathogens were
detected in the other patient’s sample. Similarly, in 1 case
of pseudomembranous colitis (PMC) all sequences were
derived with certainty from Lactobacillus rhamnosus, while
in the second case the microbiota was diverse but did not
contain Clostridium diﬃcile. One diverticulitis sample was
completely colonized by Enterobacteriaceae, while the other
showed a predominantly anaerobic adherent microbiota.International Journal of Inﬂammation 5
Table 5: Distribution of bacterial taxa over the 33 tissue samples (∗)( ∗∗).
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Phylum XII. Proteobacteria
Class III. Gammaproteobacteria
Order III. Xanthomonadales
Family I. Xanthomonadaceae 11
Order VI. Legionellales
Family I. Legionellaceae 51
Order IX. Pseudomonadales
Family II. Moraxellaceae 18
Order XII. Aeromonadales
Family II. Succinivibrionaceae 1
Order XIII. Enterobacteriales
Family I. Enterobacteriaceae 56 68 67 15 53 5 32 100
Escherichia coli 43 95
Order XIV. Pasteurellales
Family I. Pasteurellaceae 1 8
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Family I. Campylobacteraceae 8
Phylum XIII. Firmicutes
Class I. Clostridia
Order I. Clostridiales
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Family IV. Enterococcaceae 21
Enterococcus faecalis 646 International Journal of Inﬂammation
Table 5: Continued.
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(domain bacteria) 18 22 52 45 79 15 14 12 7 40 38 1 24 35 8
Family VI. Streptococcaceae 4 8 3 50
Streptococcus mitis 58
Phylum XIV. Actinobacteria
Class I. Actinobacteria
Order I. Actinomycetales
Family I. Micrococcaceae 9
Kocuria rosea 27 4
Family I. Propionibacteriaceae 13 3
Propionibacterium acnes 62 7 1 4
Phylum XX. Bacteroidetes
Class I. Bacteroidetes
Order I. Bacteroidales
Family I. Bacteroidaceae 14 7 3 50
Bacteroides fragilis 4
Bacteroides eggerthii 8
Bacteroides uniformis 3
Family III. Porphyromonadaceae 1
Family IV. Prevotellaceae 40
(∗) Numbers indicated per taxon are percentages of the total number of sequences indicated in the ﬁrst row.
(∗∗) Empty cells indicate value of 0%.
Overall however, sequence analysis of the PCR products
indicated that there might be a shift towards a nonstrictly
anaerobic microbiota in disease controls versus healthy
controls (Fisher’s Exact test: P = 0.0243).
Histological normal microdissected ileal mucosa in
Crohn’sdiseasecontainedafairlyabundant,mixedaerobic—
anaerobic microbiota. With ulceration, there was an increase
in both the number of detectable bacterial sequences and
the fraction of nonstrictly anaerobes (67% versus 62% in
normal mucosa). This underrepresentation of anaerobes in
ulcers was retained and seemed even more accentuated in
so-called pathological mucosa, which shows macroscopic
healing but is histologically still abnormal (Fisher’s Exact
test: P = 0.0138). An interesting feature of the myenteric
plexus in Crohn’s disease samples was the detection of
DNA from a single bacterial species belonging to the family
Legionellaceae. In this study, this biological signal was picked
up exclusively in CD patients carrying at least 1 copy of
either SNP8 or SNP12 of the CARD15 gene (Table 1). No
Legionellaceae were detected in controls or in the CD patient
without CD-associated CARD15 mutations. Tissue samples
from ileocolonic lymph nodes in CD patients contained
bacterial DNA, compatible with bacterial translocation.
The translocating microbiota was mixed, with a higher
proportion of strict anaerobes than in the bowel wall proper
(39% versus 18%, Fisher’s Exact test: P = 0.0007).
4. Discussion
The role of the gut microbiota in the etiopathogenesis
of Crohn’s disease is a hotly debated topic, and many
experimental protocols have been devised to investigate thisInternational Journal of Inﬂammation 7
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Figure 2: Plots of the cumulative numbers of detected genuinely present bacterial families versus the total number of bacterial sequences
analysedforCDpatients(a),diseasecontrols(b),andhealthycontrols(c).ASLC:acuteself-limitedcolitis,PMC:pseudomembranouscolitis,
DIV: diverticulitis, AC: adenocarcinoma. IL: ileum, COL: colon.
problem. In this study, we applied broad-range 16S rDNA
PCR using universal primers, followed by sequencing of PCR
products and bacterial identiﬁcation based on the obtained
sequences, an approach which has been used previously for
faecal samples and mucosal biopsies [18]. The novelty of our
approach is its application to microdissected normal tissue
structures or CD-associated lesions such as ulcerations and
architecturallyabnormal,chronicallyinﬂamedmucosa.The-
oretically, this combination would allow the identiﬁcation of
single bacterial species in well-deﬁned locations, which may
facilitate the detection of those microorganisms which are
most likely involved in CD pathogenesis. To this end, results
from CD cases were also compared with those obtained in
microdissected and non-microdissected disease and healthy
controls.
Laser capture microdissection was performed on fresh-
frozen transmural bowel biopsies obtained from surgical
samples. As part of the standard protocol, patients under-
went gut lavage prior to surgery, and broad-spectrum pre-
operative antibiotics were administered to diminish the risk
of sepsis. Also, the surgical specimens were ﬂushed with tap
water to remove residual bowel contents before transmural
biopsies were obtained. These interventions will certainly
lower the overall amount of mucosa-adherent bacteria, but8 International Journal of Inﬂammation
willnotnecessarilyeliminatethemorsigniﬁcantlydistortthe
original composition of the microbiota [23].
In this study, we microdissected 4 diﬀerent bowel wall
regions which were chosen based upon their expected infor-
mative value with regard to disease pathogenesis. The ﬁrst
areaisthemucosa,whichwasselectedsincethehighestnum-
ber of bacteria is expected in this location [24]. Additionally,
inCDadistinctioncanbemadebetweenstructurallynormal
and pathological mucosa, which may be macroscopically
intact but histologically abnormal. Ulcer beds are another
lesion of interest, given their observable histological progres-
sion, frequency, and severity in this disease. The myenteric
plexus is a well-recognizable histological landmark in bowel
resections and may thus serve as a tissue sample suitable for
thestudyofbacteriaorbacterialproductsin passagethrough
the bowel wall. Another important though not universal or
entirelyspeciﬁcfeatureofCDisepithelioidgranulomas.Two
previous studies applying LCM and molecular bacteriologi-
cal detection methods have demonstrated that these lesions
can contain DNA from MAP and Escherichia coli [25, 26].
Another study from our group, using LCM and a universal
bacterial PCR, suggested that the microbiota contained in
granulomas may be even more diverse [27]. Based on these
data,wenow hypothesize thatgranulomasin Crohn’s disease
may act as areas of containment for all kinds of translocating
bacteria. Testing this hypothesis would require a large-scale
investigation of granuloma tissue obtained from surgical
samples of patients with various genetic backgrounds, dis-
ease locations, and phenotypes. This is obviously beyond
the scope of the current study. As an alternative, we chose
to examine mesenteric lymph nodes, which also serve as a
collector and ﬁlter for all the drained lymphatic ﬂuid from
both normal and pathological bowel segments.
Almost half of the sequences which we obtained in this
study were derived from Alpha- and Betaproteobacteria,
Pseudomonadaceae, and Staphylococcaceae. According to
most previous descriptions, these taxa are distinctly uncom-
mon in both the normal faecal and mucosa-associated bowel
microbiota. We thereforeassume that they are contaminants,
which may have been present in the intact form or only as
residual DNA either in the tap water used to ﬂush the speci-
mens on the surface of presterilized gloves and consumables
or even in ultrapure water used for molecular tests [28].
Weﬁrstinvestigatedthenormalmucosa-adherentmicro-
biota in the ileum and colon of “healthy” controls, which
we deﬁned as tissue samples taken from macroscopically
normal bowel at a large distance from the tumor in patients
operated upon for colorectal adenocarcinoma. Since these
tumorswerenonstricturingandsincepreoperativegutlavage
was possible in each patient, we assume that the presence of
a tumor did not inﬂuence the composition of the mucosal
microbiota in our samples. Results were as expected with
regard to both the quantitative and qualitative aspect: the
ileum was scarcely populated while colon mucosa contained
a more abundant microbiota with a high fraction of strictly
anaerobic bacteria.
Bacterial infections are characterized by microbial pop-
ulation dynamics changing over time, which may more-
over be dependent on extraneous variables such as the
administration of anti- and possibly probiotics. Therefore
we investigated 3 types of disease controls, that is, cases
of acute self-limited colitis (a pathological entity which in
some cases has an infectious origin), pseudomembranous
colitis,anddiverticulitis(whichhasalsobeenassociatedwith
changes in the composition of the faecal microbiota) [29–
31]. Our results illustrate the disturbance of the normal
mucosal population patterns in these conditions. We did
not speciﬁcally identify Clostridium diﬃcile in the cases of
PMC. However, it should be noted that the standard toxin
assays are performed on faecal samples, and that neither the
classic assay nor the PCR for the tcdB toxin gene is entirely
speciﬁc when compared with the gold standard of sensitive
bacterial culture [32, 33]. It can thus be expected that in
some toxin-positive cases, C. diﬃcile cannot be isolated from
stool samples even with the best available culture methods. A
fortiori this would apply to mucosal biopsies which provide
a much smaller amount of starting material. Moreover it
is not known whether C. diﬃcile in pseudomembranous
colitis is mucosa-associated or dwells in the bowel lumen
or in the pseudomembranes. It is indeed diﬃcult to pin-
point the presence of speciﬁc bacterial pathogens, for which
the spatial and temporal distribution during the course of
the infectious disease is a priori unknown. Our results may
also have been inﬂuenced by the previous administration
of various courses of antibiotics or possibly even probiotics
(Lactobacillus rhamnosus) in some patients. Investigators of
the microbiota in Crohn’s disease should therefore always
take into account a history of prior antibiotic therapy or
administration of probiotics in their study subjects.
The only objective diﬀerence between histological nor-
mal ileal mucosa in Crohn’s disease cases and the healthy
control patient was the greater ease with which DNA from
genuinely present bacteria was detected in the former. We
can thus speculate that the absolute number of mucosa-
adherent bacteria is larger in CD patients compared to
controls, which ﬁts with previous reports in the literature
[34, 35]. We may further assume that the composition of the
mucosal microbiota will show additional changes with the
development of ulcerations. There are at least 2 possibilities:
somebacterialvariantsmayinduceulcers(e.g.,theadherent-
invasive subtype of Escherichia coli), or the presence of an
ulcer slough and underlying granulation tissue may confer
a selective growth advantage to particular bacterial taxa. In
this study, no speciﬁc pathogen was detected in microdis-
sected ulcer beds in Crohn’s disease. There were however
indications that these lesions may show localized bacterial
overgrowth, with shifts in the composition of the microbiota
possibly associated with an altered physicochemical milieu.
Previous studies on faecal samples have demonstrated
an abnormally high biodiversity of the microbiota in CD
patients in remission. Some harmful bacteria are increased
(e.g., Bacteroides fragilis, an opportunistic pathogen) and the
amount of protective, butyrate producing Firmicutes (e.g.,
Faecalibacterium prausnitzii) is often diminished in these
patients [16, 24, 36, 37]. This dysbiosis is apparently inde-
pendent of disease location, presence of anatomical abnor-
malities secondary to inﬂammation or scarring, treatment
with sulphasalazine or corticosteroids and even surgery.International Journal of Inﬂammation 9
Ileocolonoscopy in these patients often shows mucosal
healing, with residual signs of inactive chronic inﬂammation
on biopsy. Similar histological features can be seen in some
macroscopically normal bowel segments in surgical spec-
imens of patients operated upon for complicated Crohn’s
disease. We therefore investigated whether the mucosa-
associatedmicrobiotaisalsopersistentlyalteredinsuchareas
of microscopically “pathological mucosa.” Our results show
that this is indeed the case, with a signiﬁcant increase in
nonstrictly anaerobic taxa when compared with structurally
normal mucosa.
It has been previously proposed that viable bacteria may
be capable of crossing the intestinal mucosal barrier and
of traﬃcking to extraintestinal sites such as the mesenteric
lymph nodes, the systemic circulation, the liver and the
spleen [38, 39]. This “bacterial translocation” may be a
phenomenon that occurs in healthy individuals without
deleterious consequences. Translocation of endotoxins from
viable or dead bacteria in very small amounts probably
constitutes a physiologically important boost to the reticulo-
endothelial system, especially to the Kupﬀer cell in the liver.
The baseline rate of translocation in human studies is 5–10%
[39, 40]. Previous studies also indicate that Enterobacteri-
aceae translocate much more eﬃciently than other bacteria
(especially obligate anaerobes) [39]. Bacterial translocation
would be further promoted by 3 major conditions: intestinal
bacterial overgrowth, deﬁciencies in host immune defenses,
and increased mucosal permeability or major structural
damage to the intestinal mucosal barrier [38]. Under these
conditions, which may all be present in active Crohn’s dis-
ease, one may expect a signiﬁcant increase in the abundance
of potentially pathogenic bacteria or bacterial products in
the deeper layers of the bowel wall or in the surrounding
lymph nodes. We tested this hypothesis for 2 anatomical
compartments: the myenteric plexus as a surrogate for
bacterial traﬃcking within the bowel wall and mesenteric
lymph node tissue as the ideal locus to detect an even more
advanced and potentially more dangerous form of bacterial
translocation.
The main diﬀerence between the myenteric plexus
samplesofCDpatientsandhealthycontrolswasthepresence
ofaparticularLegionellaspeciesinsomeoftheformer,more
speciﬁcallyonlyinourCDpatientscarryingatleastonecopy
of either SNP8 or SNP12 of the CARD15 gene. The relevant
PCR product could not be identiﬁed at the species level,
but the closest relative was Legionella lytica. Legionellaceae
are gram-negative bacteria, which are able to reproduce at
temperatures between 25◦Ca n d4 3 ◦Ca n ds u r v i v ei nt e m -
peratures of up to 55–60◦C. They are therefore ubiquitous
in natural and artiﬁcial aquatic environments [41]. Since
this sequence was only detected in CD patients and not
in controls, the corresponding Legionella species may ﬁt in
the hypothesis of the persistent, still-unknown, pathogen. It
could then be placed next to Mycobacterium avium subsp.
paratuberculosis and adherent-invasive Escherichia coli which
were also initially detected in very few CD patients [8–11].
The second reason why this ﬁnding may be relevant to the
study of the etiopathogenesis of Crohn’s disease is the known
association of myenteric plexitis in the proximal margin of
surgical specimens with early clinical and histological disease
recurrence in the neoterminal ileum [42, 43].
Finally, our results on mesenteric lymph node tissues
conﬁrm the occurrence and the potential extent of bacterial
translocation in Crohn’s disease. The biological diversity
of the translocating microbiota was large, with sequences
from 8 diﬀerent families being detected. Escherichia coli
was the single most frequently detected species. Since the
ratio of facultative over strict anaerobic bacteria was 1.47,
facultative anaerobes may translocate more eﬃciently at
larger distances.
5. Conclusion
In this study, we investigated alterations in the mucosa-
associated and translocating bowel microbiota in Crohn’s
disease patients, disease controls, and healthy controls. We
used a new approach consisting of laser capture microdissec-
tion of selected microscopic structures, followed by broad-
range 16S rDNA PCR with universal primers. Our ﬁndings
in healthy and disease controls are compatible with previous
culture-based and molecular studies. They underline the sig-
niﬁcance of biopsy location and prior or concurrent antimi-
crobial therapy for a correct interpretation of the composi-
tion of the mucosa-associated bowel microbiota. Our results
in Crohn’s disease point to important spatiotemporal alter-
ations of the gut microbiome in this condition. The compo-
sition and abundance of the mucosa-associated microbiota
changes with the presence of mucosal defects and seems to
remain abnormal upon macroscopic healing. There are also
indications of increased bacterial translocation, possibly by
uncommonbacterialspecieswhichmayﬁndanewecological
niche in the inﬂamed bowel wall. Further investigations
using the combination of LCM and universal 16S rDNA PCR
may lead to a better understanding of the role of the bowel
microbiota in the etiopathogenesis of Crohn’s disease.
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